NCT02414919已完成不适用
Real-world Duration of Use for Highly Effective Reversible Contraception (HERC): A Retrospective Review
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 13,880
- 主要终点
- Proportion of women who use HERC
研究概览
简要总结
To assess the proportion of women who use HERC for ≥2 years of duration
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 15 Years 至 44 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012
排除标准
- 未提供
研究组 & 干预措施
HERC
Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
干预措施: Mirena (Levonorgestrel IUS, BAY86-5028) (Drug)
HERC
Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
干预措施: ParaGard (Drug)
HERC
Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
干预措施: Implanon/Nexplanon (Drug)
结局指标
主要结局
Proportion of women who use HERC
时间窗: 2 years post-HERC initiation
次要结局
- Duration of real world use of three different HERC devices(2 years post-HERC initiation)
研究者
相似试验
已完成
不适用
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or AlpelisibHormone Receptor Positive HER-2 Negative Breast CancerNCT06705504Novartis435
撤回
2 期
Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete ResponseHER2-positive Breast CancerBreast CancerNCT05371860Armando Giuliano
招募中
2 期
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical SurgeryUpper Urinary Tract Urothelial CarcinomaNCT06210490Peking University First Hospital60
尚未招募
4 期
Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast CancerBreast Cancer Stage IVNCT06578299Fudan University100
进行中（未招募）
不适用
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in FranceBreast CancerNCT05697146Novartis Pharmaceuticals1,019